More active enantiomer of (RS)-Baclofen (Cat. No. 0417), a selective GABAB agonist.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||4.27||20mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 213.66. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.68 mL||23.4 mL||46.8 mL|
|5 mM||0.94 mL||4.68 mL||9.36 mL|
|10 mM||0.47 mL||2.34 mL||4.68 mL|
|50 mM||0.09 mL||0.47 mL||0.94 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Falch et al (1986) Comparative stereostructure-activity studies on GABAA and GABAB receptor sites and GABA uptake using rat brain membrane preparations. J.Neurochem. 47 898 PMID: 3016189
Hong et al (1991) Effects of phaclofen and the enantiomers of baclofen on cardiovascular responses to intrathecal administration of L- and D-baclofen in the rat. Eur.J.Pharmacol. 196 267 PMID: 1654254
If you know of a relevant reference for (R)-Baclofen, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (R)-Baclofen, supplier, Selective, GABAB, agonists, Receptors, STX209, STX, 209, GABAB, Receptors, GABAB, Receptors, Tocris Bioscience
10 Citations for (R)-Baclofen
Citations are publications that use Tocris products. Selected citations for (R)-Baclofen include:
Bragina et al (2015) Differential expression of metabotropic glutamate and GABA receptors at neocortical glutamatergic and GABAergic axon terminals. Front Cell Neurosci 9 345 PMID: 26388733
Kirwan et al (2015) Development and function of human cerebral cortex neural networks from pluripotent stem cells in vitro. J Pharmacol Exp Ther 142 3178 PMID: 26395144
Zhang et al (2015) GABAB receptor upregulates fragile X mental retardation protein expression in neurons. Front Cell Neurosci 5 10468 PMID: 26020477
Wang et al (2015) Neuronal γ-aminobutyric acid (GABA) type A receptors undergo cognate ligand chaperoning in the endoplasmic reticulum by endogenous GABA. Mol Cell Neurosci 9 188 PMID: 26041994
Xia et al (2014) Regulation of action potential waveforms by axonal GABAA receptors in cortical pyramidal neurons. PLoS One 9 e100968 PMID: 24971996
Hensler et al (2012) GABAB receptor-positive modulators: brain region-dependent effects. J Pharmacol Exp Ther 340 19 PMID: 21954301
Pacey et al (2011) Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome. Sci Rep 338 897 PMID: 21636656
Lobb et al (2010) A dynamic role for GABA receptors on the firing pattern of midbrain dopaminergic neurons. J Neurophysiol 104 403 PMID: 20445035
Bartoi et al (2010) GABAB receptor constituents revealed by tandem affinity purification from transgenic mice. J Biol Chem 285 20625 PMID: 20406808
Piqueras and Martínez (2004) Peripheral GABAB agonists stimulate gastric acid secretion in mice. Br J Pharmacol 142 1038 PMID: 15210585
Do you know of a great paper that uses (R)-Baclofen from Tocris? If so please let us know.
Literature in this Area
GABA Receptors Scientific Review
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.